Alcohol Monitor Validation

Not Applicable

Completed

Brief Summary: This study will validate a wrist-worn alcohol monitor (BACtrack Skyn) in both laboratory and real-life settings.

Detailed Description: The overarching goal of this research program is to improve alcohol intervention and eventually related clinical outcomes (e.g., liver function) among HIV+ drinkers through biosensor-assisted intervention. Research shows HIV infection can influence alcohol metabolism (i.e., higher blood alcohol levels), so it's necessary to validate the new alcohol biosensor in HIV+ drinkers rather than in general population. The primary goal of this project, as a step toward the development and evaluation of a biosensor-assisted alcohol intervention, is to validate the newly available wrist worn transdermal alcohol biosensor (BACtrack Skyn). The two specific aims are: (1) To assess validity and reliability of the Skyn biosensor using fixed-dose lab administration of alcohol through comparison with laboratory grade breathalyzer, and (2) To validate Skyn biosensor in daily life using a 2-week ecological momentary assessment (EMA) to compare self-reported drinking and the Skyn derived transdermal alcohol concentration (TAC) readings.

Recruitment & Eligibility

Inclusion Criteria

HIV+ consumers of alcohol; self-reported ≥ 5 days with at least 1 alcoholic drink, and ≥1days with at least 3 drinks
HIV- consumers of alcohol; self-reported ≥ 5 days with at least 1 alcoholic drink, and ≥1days with at least 3 drinks

Exclusion Criteria

non-drinkers
recent addiction treatment or treatment seeking
urine positive for illegal drugs except THC (not applicable to those who are only invited to do field test);
past & current alcohol withdrawal
severe alcohol use disorder (DSM-5)
meeting criteria for current nicotine dependence (not applicable to field only participants) or current substance use disorder (excluding mild cannabis use disorder and mild/moderate alcohol use disorder)
medical conditions (other than HIV) contraindicating alcohol
pregnancy/breastfeeding in women
psychosis or other severe psychiatric conditions.

Primary Outcome Measures

Name	Time	Method
Transdermal Alcohol Concentration (TAC)	2 weeks	Here we reported mean and SD of peak TAC in the laboratory sessions and in the field test.

Secondary Outcome Measures

Name	Time	Method

Locations (2): HealthStreet
🇺🇸
Gainesville, Florida, United States
University of Florida
🇺🇸
Gainesville, Florida, United States
HealthStreet
🇺🇸Gainesville, Florida, United States